Reuters logo
BRIEF-Cytokinetics announces first patient enrolled in VIGOR-ALS
October 18, 2016 / 11:51 AM / a year ago

BRIEF-Cytokinetics announces first patient enrolled in VIGOR-ALS

Oct 18 (Reuters) - Cytokinetics Inc :

* Cytokinetics announces first patient enrolled in VIGOR-ALS, an open-label extension clinical trial of tirasemtiv Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below